可解释性
医学
不利影响
不良事件报告系统
药物警戒
逻辑回归
机器学习
梯度升压
人工智能
重症监护医学
急诊医学
多项式logistic回归
内科学
多药
梅德林
肿瘤科
药物流行病学
Boosting(机器学习)
风险评估
事件数据
支持向量机
食品药品监督管理局
特征(语言学)
F1得分
有序逻辑
随机森林
药物不良反应
精密医学
作者
Luke Xiyu Zhao,Catherine Wang,Jonathan Zou,Padmini D Ranasinghe
摘要
PURPOSE: Predicting severe adverse events (SAEs) in oncology is challenging because of complex therapies and patient heterogeneity. Traditional pharmacovigilance methods often fail to capture multifactorial risk patterns. Machine learning (ML) offers potential to identify subtle predictors of SAEs within large real-world data sets such as the US Food and Drug Administration Adverse Event Reporting System (FAERS). This study developed and validated an ML model to predict severe oncology-related adverse events and identify key risk factors using FAERS data. METHODS: We analyzed 3,789,273 unique oncology-related FAERS cases (2012Q4-2024Q3) after extensive preprocessing, including natural language processing-based indication filtering, deduplication, and variable standardization. Severe events were defined by outcomes of death, hospitalization, disability, congenital anomaly, or life-threatening condition. A LightGBM model was trained using Optuna-based hyperparameter optimization and benchmarked against logistic regression. Model performance was evaluated using AUROC, AUPRC, precision, recall, and F1-score. Shapley Additive Explanations (SHAP) analysis assessed the feature influence and interpretability. RESULTS: 71.6%). Key predictors of severity included advanced age, higher weight, extensive polypharmacy (median 15 drugs; IQR, 9-27), longer therapy duration (median 6.3 days), and greater numbers of reported reactions (mean 5 per case). SHAP analysis revealed that age, polypharmacy, and therapy duration synergistically increased SAE risk. CONCLUSION: Our gradient boosting model substantially improved prediction and interpretability of severe oncology adverse events compared with logistic regression. SHAP analysis identified clinically meaningful predictors, enabling precision pharmacovigilance and targeted risk mitigation. These findings support ML integration into regulatory and clinical pharmacovigilance workflows to enhance postmarket safety surveillance.
科研通智能强力驱动
Strongly Powered by AbleSci AI